about
Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosisPredictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fractureThe use of bisphosphonates in women: when to use and when to stop.The application of absolute quantitative (1)H NMR spectroscopy in drug discovery and development.Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial.Atraumatic femoral neck fracture during bisphosphonate treatment: case report and review of the literature.
P2860
Q34758140-6C694752-5BA9-4E7B-ACB8-0DC3486135E8Q35940958-3A23424C-40D3-4567-838C-A45FF6121557Q37048294-FD725555-1F63-4D34-A34E-D30E278D88E8Q38584336-6627B7EA-60E8-49E0-BA85-D0A210B38788Q38836228-1D8A949F-7677-464B-8F29-D971B8C0EEFAQ42353384-31A2689F-09C4-44AC-974F-4C9DC85C4233Q48110369-4F0BBFB2-7B2A-4932-893D-58DFFECD05D3
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Osteoporosis treatment: why ibandronic acid?
@en
type
label
Osteoporosis treatment: why ibandronic acid?
@en
prefLabel
Osteoporosis treatment: why ibandronic acid?
@en
P2860
P50
P1476
Osteoporosis treatment: why ibandronic acid?
@en
P2093
Giovanni Orsolini
Silvano Adami
P2860
P304
P356
10.1517/14656566.2013.795949
P407
P577
2013-05-07T00:00:00Z